<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01265160</url>
  </required_header>
  <id_info>
    <org_study_id>81929</org_study_id>
    <nct_id>NCT01265160</nct_id>
  </id_info>
  <brief_title>Jiangzhuo Prescription ，Fenofibrate and Placebo in the Treatment of Hyperlipidemia (Syndrome of Phlegm Obstruction)Clinical Study (JZF)</brief_title>
  <acronym>JZF</acronym>
  <official_title>Jiangzhuo Prescription ，Fenofibrate and Placebo in the Treatment of Hyperlipidemia (Syndrome of Phlegm Obstruction)Clinical Study (JZF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Jiangzhuo prescription ,fenofibrate and placebo in the treatment of hyperlipidemia(syndrome
      of phlegm obstruction), randomized, parallel-controlled, multi-center clinical study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Charged by the five research centers in line with traditional Chinese medicine syndrome of
      phlegm obstruction 240 cases have hyperlipidemia, and overweight, as well as hypertension or
      diabetes were randomly divided into Chinese herbal compound Jiangzhuo prescription group and
      western medicine fenofibrate group and placebo group.The treatment groups were compared
      12-week regulation of blood lipids and step-down, blood sugar effect.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">May 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Metabolic Syndromes</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>the group of Jiangzhuo prescription</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>the group of fenofibrate</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>the group of placebo</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Combined metabolic syndrome in patients with hyperlipidemia
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Consistent with diagnosed hyperlipidemia, TG≥2.26mmol/L and ≤7.0mmol/L. 2. Aged
             18-65 years old. 3.BMI ≥ 24kg/m2, but &lt;35 kg/m2. 4. Waist circumference ≥ 90cm (male)
             or waist circumference ≥ 80cm (women). 5. Comply with any of the following 3 :bloode
             pressure elevated levels of:SBP ≥130mmHg or DBP ≥85mmHg; fasting plasma glucose (FPG)
             increased: FPG ≥ 100mg/dl (5.6mmol / l ), or previously diagnosed type 2 diabetes or
             have received appropriate treatment.

        Exclusion Criteria:

          -  1. Has been used to control lipidsdrugs, but use the time for those below the 3 month.

             2.Secondary dyslipidemia, such as nephrotic syndrome, hyperthyroidism, etc. 3.Taking
             thyroid medications and other drugs that affect lipid metabolism, such as high-dose
             thiazide diuretics, β-receptor blockers, corticosteroids.

             4.Severe diseases of heart, lung, liver, kidney, brain, blood ,etc. 5.With the
             treatment of insulin, sulfonylureas, rosiglitazone or metformin. 6.3 months prior to
             the study of myocardial infarction or unstable angina confirmed.

             7.Uncontrolled blood sugar or after controlling FPG&gt;7.0mmol/L or 2hPG&gt;11.1mmol/L
             8.Uncontrolled blood pressure or after contraolling blood pressure&gt;140/90mmHg
             9.ALT≥80mmol/L 10.Pregnancy, for pregnancy or breast-feeding women 11.Allergis of
             fibrates or Chinese medicine 12.Mental illness 13.Cancer patients 14.History of
             gallbladder disease or cholelithiasis 15.With the treatment of Cyclosporine or
             coumarin anticoagulants 16.The patient with other clinical studies in the past 3
             months 17.History of alcoholism and drug dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fengmei Lian, PHD</last_name>
    <phone>0086-010-88001402</phone>
    <email>lfm565@sohu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Chinese Medicine Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bai Chang, PHD</last_name>
      <phone>13611089962</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Ji Shui Tan Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xia Wang</last_name>
      <phone>13681007636</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Medical University,DONGZHIMEN Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongfang Liu, PHD</last_name>
      <phone>0086-010-84013243</phone>
      <email>lhfdoctor@sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Civil Aviation General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Zhao, PHD</last_name>
      <phone>13522424090</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2010</study_first_submitted>
  <study_first_submitted_qc>December 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2010</study_first_posted>
  <last_update_submitted>December 22, 2010</last_update_submitted>
  <last_update_submitted_qc>December 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</name_title>
    <organization>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

